SCHEMBL16028693

SCHEMBL16028693

CS(=O)(=O)OC1CC(C(=O)OCc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
STS P08842 1/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.43
FABP7 O15540 1/20 0.43
FABP5 Q01469 1/20 0.43
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
NAMPT P43490 1/20 0.42
PKM P14618 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3722755 1.00 ALDH1A1 (0.45) ALDH1A1STSHPGDTSHRFABP7
SCHEMBL25642132 0.89 TSHR (0.47) ALDH1A1STSHPGDTSHRPKM
SCHEMBL30288744 0.89 TSHR (0.47) ALDH1A1STSHPGDTSHRPKM
SCHEMBL25642131 0.89 TSHR (0.47) ALDH1A1STSHPGDTSHRPKM
SCHEMBL735852 0.88 PKM (0.49) ALDH1A1HPGDTSHRFABP7FABP5
SCHEMBL735851 0.88 PKM (0.49) ALDH1A1HPGDTSHRFABP7FABP5
SCHEMBL16708933 0.83 ALDH1A1 (0.47) ALDH1A1STSHPGDTSHRFABP7
SCHEMBL18717596 0.82 ALDH1A1 (0.50) ALDH1A1HPGDTSHRFABP7FABP5
SCHEMBL1503740 0.82 ALDH1A1 (0.50) ALDH1A1HPGDTSHRFABP7FABP5
SCHEMBL23887710 0.82 CA1 (0.53) ALDH1A1STSHPGDCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319698-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2025-06-03 US disclosed
CN-112585132-B Proteasome activity enhancing compounds 优曼尼蒂公司 2025-02-28 CN disclosed
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 US disclosed
US-11958854-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2024-04-16 US disclosed
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS YUMANITY THERAPEUTICS, INC. 2023-06-15 US disclosed
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2023-02-09 US disclosed
US-11560385-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2023-01-24 US disclosed
WO-2022108507-A1 Chemoselective probes and uses thereof LIN WEIFENG (SE) 2022-05-27 WO disclosed
US-11208409-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2021-12-28 US disclosed
CN-107082782-B Substituted xanthines and methods of use thereof 海德拉生物科学有限责任公司 2020-03-20 CN disclosed
EP-2970303-A2 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF Hydra Biosciences, Inc. (US) 2016-01-20 EP disclosed
US-20150328228-A1 NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE ITEOS THERAPEUTICS (BE) 2015-11-19 US disclosed
US-9126984-B2 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use ITEOS THERAPEUTICS SA (BE) 2015-09-08 US disclosed
WO-2015067782-A1 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE ITEOS THERAPEUTICS (BE) 2015-05-14 WO disclosed
US-20150133422-A1 NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE ITEOS THERAPEUTICS SA (BE) 2015-05-14 US disclosed
WO-2014143799-A9 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-12-24 WO disclosed
WO-2014143799-A9 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-12-24 WO disclosed
WO-2014143799-A2 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 WO disclosed
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133422-A1 NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TDO2, IDO1, IDO2 ALDH1A1 577/4885STS 1272/4885HPGD 548/4885
US-11560385-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 ALDH1A1 3438/4885STS 2204/4885HPGD 3178/4885
US-12319698-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 ALDH1A1 3438/4885STS 2204/4885HPGD 3178/4885
US-11958854-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885STS 2607/4885HPGD 1050/4885
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885STS 2607/4885HPGD 1050/4885
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885STS 2607/4885HPGD 1050/4885
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885STS 2607/4885HPGD 1050/4885
US-20150328228-A1 NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TDO2, IDO1, IDO2 ALDH1A1 737/4885STS 1510/4885HPGD 445/4885
US-11208409-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 ALDH1A1 1647/4885STS 2607/4885HPGD 1050/4885
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSME3, PSMC4 ALDH1A1 3438/4885STS 2204/4885HPGD 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.